RenovoRx Inc.
71 articles about RenovoRx Inc.
-
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
4/18/2024
RenovoRx, Inc. announced that, in light of its recent successful fundraising activity, it has received written confirmation from The Nasdaq Stock Market LLC that the Company has regained compliance with the $2.5 million minimum stockholders’ equity requirement in Nasdaq Listing Rule 5550.
-
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
4/16/2024
RenovoRx, Inc today highlights a presentation of a clinical data abstract at the recent 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-27, 2024 in Salt Lake City, Utah.
-
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
4/15/2024
RenovoRx, Inc. today announced the closing of its previously announced private placement of approximately $11.1 million in gross proceeds.
-
RenovoRx Announces $11.1 Million at Market Private Placement
4/8/2024
RenovoRx, Inc. today announced the execution of definitive subscription agreements with accredited investors for a private placement which is expected to result in gross proceeds of approximately $11.1 million to RenovoRx, before deducting offering expenses.
-
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
4/5/2024
RenovoRx, Inc today announced that Shaun Bagai, RenovoRx’s Chief Executive Officer, will present at the Canaccord Genuity 2024 Horizons in Oncology Virtual Conference to be held on April 15, 2024.
-
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
3/12/2024
RenovoRx, Inc today announced that Shaun Bagai, RenovoRx’s Chief Executive Officer, will present at the 36th Annual ROTH Conference to be held March 17-19, 2024 in Dana Point, CA.
-
RenovoRx Highlights Key Leadership Promotions - March 08, 2024
3/8/2024
RenovoRx, Inc., a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, highlighted the recent key leadership promotions of Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak, CPA to Principal Accounting Officer.
-
RenovoRx CEO Issues Letter to Shareholders
2/6/2024
Recent financing will drive Company towards second interim analysis on pivotal Phase III TIGeR-PaC clinical trial by end of 2024.
-
RenovoRx Closes $6.1 Million Private Placement
1/29/2024
RenovoRx, Inc. today announced that it has closed a private placement (the “private placement” or the “financing”) resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses.
-
BioSpace spoke with industry professionals about how to make your time in San Francisco valuable.
-
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
12/21/2023
RenovoRx, Inc today announced the expansion of their clinical development pipeline in preparation for the commencement of a second Phase III trial.
-
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
12/19/2023
RenovoRx, Inc today announced the acceptance of a clinical data abstract for the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-28 in Salt Lake City, Utah.
-
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
12/13/2023
RenovoRx, Inc. announced today that the Company has filed an international patent application under the Patent Cooperation Treaty (PCT) for its novel Trans-Arterial Micro-Perfusion (TAMP) therapy platform.
-
RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
11/16/2023
RenovoRx, Inc today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company’s Scientific Advisory Board (SAB).
-
RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023
10/2/2023
RenovoRx, Inc today announced that CEO, Shaun Bagai, will present at the ROTH MKM Healthcare Opportunities Conference in New York on October 12, 2023.
-
RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights
8/17/2023
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the second quarter ended June 30, 2023.
-
RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference
7/31/2023
RenovoRx, Inc today announced that its CEO Shaun Bagai will provide a corporate overview and update at the 43rd Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2023 at 10:30 AM ET in Boston, MA.
-
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
7/20/2023
RenovoRx, Inc and Imugene Ltd today announced a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.
-
RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer
6/29/2023
RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem ™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer.
-
RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board
6/20/2023
RenovoRx, Inc today announced the appointment of Margaret A. Tempero, M.D., Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program, to the Company’s Scientific Advisory Board (SAB).